Chase Medical Research, LLC

Summary

Chase Medical Research, LLC is a medical facility located in Waterbury, Connecticut. This center is recognized for care of Type 2 Diabetes, Obesity, Diabetes, Childhood Obesity, Cardiovascular Disease and other specialties. Chase Medical Research, LLC is involved with conducting 84 clinical trials across 97 conditions. There are 1 research doctors associated with this hospital, such as Joseph Soufer.

Top PIs

Clinical Trials running at Chase Medical Research, LLC

Cardiovascular Disease

High Blood Pressure

Hypertension

Obesity

Type 2 Diabetes

Atherosclerosis

Childhood Obesity

Osteoarthritis Treatment Costs

Rheumatoid Arthritis

Lipid Overnutrition

Vicadrostat + Empagliflozin

for Type 2 Diabetes and Hypertension

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

4 criteria

Olpasiran

for Cardiovascular Disease

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Recruiting

1 award

Phase 3

2 criteria

Lepodisiran

for Cardiovascular Disease

This trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.

Recruiting

1 award

Phase 3